Emergence of Linezolid Resistant Enterococ- cus Faecalis Co-producing blacfr and blaoptrA in China

Qingqing Chen,Dandan Yin,Pei Li,Yan Guo,Desong Ming,Yuling Lin,Xiaoli Yan,Zhishan Zhang,Fupin Hu

2020-01-01

Abstract:Linezolid is considered as a last resort drug in treatment of severe infections caused by multidrug-resistant gram-positive pathogens, such as vancomycin-resistant Enterococcus spp. (VRE), methicillin-resistant Staphylococcus spp. and Streptococcus pneumoniae [1]. Although most gram-positive pathogenic bacteria remain susceptible to linezolid, resistant isolates of Enterococci have been reported worldwide. The resistance mechanism of Enterococcus spp. to linezolid is in addition to the mutation of 23S rRNA gene, and the acquired resistance genes such as blacfr, blacfr(B), blaoptrA and blapoxtA. The blacfr and blacfr(B) genes encode a rRNA methyltransferase causes oxazolidinones, chloramphenicols, tetracycline, lincomycins, pleuromutilin and streptavidin A resistance and macrolide sensitivity decreased [2-7]. Until now, the co-occurrence of blacfr or blacfr(B) and blaoptrA, blapoxtA along with blaoptrA has been reported on the same plasmid in Enterococcus faecalis, Staphylococcus sciuri or Enterococcus spp. from swine and farm environment [8-11]. Here, we firstly reported the emergence of linezolid-resistant Enterococcus faecalis clinical strain co-producing blacfr and blaoptrA, which were located on different plasmids in China.